Avalo Net Receivables vs Accounts Payable Analysis

AVTX Stock

USD 9.23 0.12 1.32%

Avalo Therapeutics financial indicator trend analysis is way more than just evaluating Avalo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avalo Therapeutics is a good investment. Please check the relationship between Avalo Therapeutics Net Receivables and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avalo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avalo Therapeutics Net Receivables account and Accounts Payable. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Avalo Therapeutics' Net Receivables and Accounts Payable is 0.41. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Avalo Therapeutics, assuming nothing else is changed. The correlation between historical values of Avalo Therapeutics' Net Receivables and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of Avalo Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Receivables i.e., Avalo Therapeutics' Net Receivables and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.41

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Receivables

Accounts Payable

An accounting item on the balance sheet that represents Avalo Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Avalo Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Avalo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avalo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avalo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.At this time, Avalo Therapeutics' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 32.5 K in 2024, whereas Discontinued Operations is likely to drop (32.6 K) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	2.4M	4.2M	3.4M	5.6M
Depreciation And Amortization	1.7M	166K	158K	150.1K

Interest Expense Depreciation And Amortization

Avalo Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt	Net Receivables	Inventory	Other Liab	Net Tangible Assets
Total Assets		0.9	0.85	0.78	0.61	-0.27	-0.48	0.45	0.66	0.82	-0.09	0.68	-0.07	0.19	0.54	0.56	0.57	0.81	0.21	0.61	0.63	-0.3	0.83	0.54	0.48	0.31
Other Current Liab	0.9		0.96	0.64	0.58	0.04	-0.36	0.58	0.44	0.89	-0.1	0.47	-0.23	0.18	0.54	0.42	0.65	0.64	0.18	0.58	0.48	-0.13	0.91	0.66	0.61	0.3
Total Current Liabilities	0.85	0.96		0.55	0.59	0.08	-0.37	0.61	0.48	0.8	-0.17	0.5	-0.32	0.22	0.49	0.4	0.69	0.65	0.1	0.63	0.44	0.12	0.84	0.6	0.6	0.22
Total Stockholder Equity	0.78	0.64	0.55		0.41	-0.38	-0.35	0.15	0.38	0.71	-0.35	0.43	-0.05	-0.43	0.47	0.47	-0.04	0.57	0.4	0.16	0.46	-0.46	0.66	0.38	0.21	0.33
Property Plant And Equipment Net	0.61	0.58	0.59	0.41		-0.27	-0.87	0.57	0.59	0.35	-0.01	0.63	0.28	0.15	0.53	0.85	0.43	0.64	-0.19	0.38	0.5	-0.01	0.33	-0.12	0.04	-0.16
Net Debt	-0.27	0.04	0.08	-0.38	-0.27		0.18	-0.18	-0.7	0.2	-0.25	-0.69	-0.05	-0.02	-0.52	-0.22	0.07	-0.62	0.09	-0.07	-0.77	0.42	0.13	0.39	0.42	-0.42
Retained Earnings	-0.48	-0.36	-0.37	-0.35	-0.87	0.18		-0.15	-0.38	-0.32	0.22	-0.38	-0.65	-0.02	-0.39	-0.99	-0.19	-0.37	0.15	-0.15	-0.24	0.01	-0.1	0.13	-0.1	0.52
Accounts Payable	0.45	0.58	0.61	0.15	0.57	-0.18	-0.15		0.55	0.19	0.45	0.58	-0.48	0.35	0.54	0.13	0.61	0.63	-0.06	0.64	0.65	0.17	0.41	-0.05	-0.07	0.42
Cash	0.66	0.44	0.48	0.38	0.59	-0.7	-0.38	0.55		0.13	0.31	0.99	-0.14	0.48	0.47	0.4	0.57	0.95	-0.14	0.67	0.87	-0.07	0.3	-0.05	0.01	0.35
Non Current Assets Total	0.82	0.89	0.8	0.71	0.35	0.2	-0.32	0.19	0.13		-0.33	0.15	-0.03	-0.05	0.35	0.4	0.39	0.36	0.41	0.37	0.2	-0.26	0.88	0.81	0.7	0.13
Non Currrent Assets Other	-0.09	-0.1	-0.17	-0.35	-0.01	-0.25	0.22	0.45	0.31	-0.33		0.29	-0.12	0.57	0.02	-0.26	0.35	0.21	-0.16	0.44	0.39	-0.09	-0.13	-0.24	-0.22	0.3
Cash And Short Term Investments	0.68	0.47	0.5	0.43	0.63	-0.69	-0.38	0.58	0.99	0.15	0.29		-0.16	0.44	0.46	0.4	0.55	0.97	-0.16	0.65	0.85	-0.11	0.35	-0.07	-0.02	0.39
Common Stock Shares Outstanding	-0.07	-0.23	-0.32	-0.05	0.28	-0.05	-0.65	-0.48	-0.14	-0.03	-0.12	-0.16		-0.05	-0.03	0.63	-0.22	-0.23	-0.19	-0.35	-0.23	-0.28	-0.34	-0.23	-0.01	-0.68
Non Current Liabilities Total	0.19	0.18	0.22	-0.43	0.15	-0.02	-0.02	0.35	0.48	-0.05	0.57	0.44	-0.05		-0.03	-0.05	0.85	0.38	-0.29	0.65	0.3	0.17	0.1	0.1	0.24	0.08
Other Current Assets	0.54	0.54	0.49	0.47	0.53	-0.52	-0.39	0.54	0.47	0.35	0.02	0.46	-0.03	-0.03		0.43	0.24	0.53	-0.08	0.11	0.74	-0.27	0.29	0.04	0.06	0.36
Other Stockholder Equity	0.56	0.42	0.4	0.47	0.85	-0.22	-0.99	0.13	0.4	0.4	-0.26	0.4	0.63	-0.05	0.43		0.16	0.41	-0.09	0.14	0.28	-0.09	0.17	-0.07	0.13	-0.45
Total Liab	0.57	0.65	0.69	-0.04	0.43	0.07	-0.19	0.61	0.57	0.39	0.35	0.55	-0.22	0.85	0.24	0.16		0.6	-0.15	0.81	0.45	0.17	0.53	0.39	0.48	0.19
Total Current Assets	0.81	0.64	0.65	0.57	0.64	-0.62	-0.37	0.63	0.95	0.36	0.21	0.97	-0.23	0.38	0.53	0.41	0.6		-0.03	0.69	0.87	-0.18	0.55	0.12	0.11	0.47
Common Stock	0.21	0.18	0.1	0.4	-0.19	0.09	0.15	-0.06	-0.14	0.41	-0.16	-0.16	-0.19	-0.29	-0.08	-0.09	-0.15	-0.03		0.24	0.01	-0.14	0.22	0.26	-0.08	0.06
Short Long Term Debt Total	0.61	0.58	0.63	0.16	0.38	-0.07	-0.15	0.64	0.67	0.37	0.44	0.65	-0.35	0.65	0.11	0.14	0.81	0.69	0.24		0.54	0.22	0.49	0.3	0.26	0.2
Current Deferred Revenue	0.63	0.48	0.44	0.46	0.5	-0.77	-0.24	0.65	0.87	0.2	0.39	0.85	-0.23	0.3	0.74	0.28	0.45	0.87	0.01	0.54		-0.32	0.33	-0.03	-0.07	0.59
Short Term Debt	-0.3	-0.13	0.12	-0.46	-0.01	0.42	0.01	0.17	-0.07	-0.26	-0.09	-0.11	-0.28	0.17	-0.27	-0.09	0.17	-0.18	-0.14	0.22	-0.32		-0.28	-0.15	0.0	-0.46
Net Receivables	0.83	0.91	0.84	0.66	0.33	0.13	-0.1	0.41	0.3	0.88	-0.13	0.35	-0.34	0.1	0.29	0.17	0.53	0.55	0.22	0.49	0.33	-0.28		0.77	0.64	0.46
Inventory	0.54	0.66	0.6	0.38	-0.12	0.39	0.13	-0.05	-0.05	0.81	-0.24	-0.07	-0.23	0.1	0.04	-0.07	0.39	0.12	0.26	0.3	-0.03	-0.15	0.77		0.91	0.23
Other Liab	0.48	0.61	0.6	0.21	0.04	0.42	-0.1	-0.07	0.01	0.7	-0.22	-0.02	-0.01	0.24	0.06	0.13	0.48	0.11	-0.08	0.26	-0.07	0.0	0.64	0.91		-0.01
Net Tangible Assets	0.31	0.3	0.22	0.33	-0.16	-0.42	0.52	0.42	0.35	0.13	0.3	0.39	-0.68	0.08	0.36	-0.45	0.19	0.47	0.06	0.2	0.59	-0.46	0.46	0.23	-0.01

Click cells to compare fundamentals

Avalo Therapeutics Account Relationship Matchups

Avalo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	36.1M	43.8M	80.2M	33.4M	21.0M	37.3M
Other Current Liab	10.1M	12.2M	16.0M	12.7M	3.6M	3.5M
Total Current Liabilities	12.2M	15.2M	19.9M	22.1M	4.6M	4.4M
Total Stockholder Equity	21.0M	24.6M	23.1M	(10.9M)	7.3M	8.3M
Property Plant And Equipment Net	1.4M	1.6M	2.7M	2.4M	2.0M	1.1M
Net Debt	(2.3M)	(18.5M)	(21.8M)	6.2M	(6.9M)	(7.2M)
Retained Earnings	(114.3M)	(177.8M)	(262.2M)	(303.8M)	(335.1M)	(318.4M)
Accounts Payable	2.1M	2.6M	3.4M	2.9M	446K	423.7K
Cash	3.6M	18.9M	54.6M	13.2M	7.4M	7.0M
Non Current Assets Total	18.4M	17.8M	18.4M	17.0M	12.6M	16.6M
Non Currrent Assets Other	102K	149K	1.2M	131K	117.9K	112.0K
Cash And Short Term Investments	11.2M	18.9M	54.6M	13.2M	7.4M	7.0M
Common Stock Shares Outstanding	19.8K	25.5K	36.2K	39.2K	277.7K	291.6K
Liabilities And Stockholders Equity	36.1M	43.8M	80.2M	33.4M	21.0M	37.3M
Non Current Liabilities Total	3.0M	4.0M	37.2M	22.2M	9.1M	12.1M
Other Current Assets	707K	4.9M	2.4M	1.3M	844K	1.4M
Other Stockholder Equity	135.2M	202.3M	285.1M	292.9M	342.4M	359.6M
Total Liab	15.1M	19.2M	57.1M	44.3M	13.7M	13.0M
Total Current Assets	17.7M	26.0M	61.8M	16.4M	8.4M	8.0M
Common Stock	44K	75K	113K	9K	1K	950.0
Short Long Term Debt Total	1.3M	426.3K	32.8M	19.4M	537K	510.2K
Current Deferred Revenue	(155.8K)	10.9M	16.0M	88K	101.2K	96.1K
Short Term Debt	155.8K	426K	485K	6.5M	537K	510.2K
Net Receivables	5.2M	2.2M	4.8M	1.9M	136K	129.2K
Inventory	1.1M	21K	3K	38K	20K	0.0
Other Liab	1.8M	2.9M	4.4M	7.0M	6.3M	5.8M
Net Tangible Assets	4.2M	8.6M	8.6M	(25.3M)	(22.8M)	(21.7M)
Other Assets	101.9K	148.6K	1.2M	1.0	0.9	0.86
Net Invested Capital	21.0M	24.6M	55.9M	8.5M	7.3M	6.9M
Property Plant And Equipment Gross	1.4M	1.6M	3.0M	2.8M	2.5M	1.9M
Non Current Liabilities Other	1.1M	3.9M	4.3M	3.7M	3.4M	3.3M
Net Working Capital	5.6M	10.8M	42.0M	(5.7M)	3.8M	3.6M
Intangible Assets	31.2M	2.4M	1.6M	38K	34.2K	32.5K
Property Plant Equipment	1.4M	1.6M	2.7M	2.4M	2.8M	1.6M
Capital Stock	47.2K	76.3K	113K	9K	1K	950.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Avalo Net Receivables vs Accounts Payable Analysis

Net Receivables vs Accounts Payable

Net Receivables vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Receivables

Accounts Payable

Avalo Therapeutics fundamental ratios Correlations

Avalo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Avalo Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Avalo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.97	Cash And Short Term Investments
Total Current Liabilities	+ 0.96	Other Current Liab
Total Current Assets	+ 0.95	Cash
Net Receivables	+ 0.91	Other Current Liab
Other Liab	+ 0.91	Inventory

Other Stockholder Equity	- 0.99	Retained Earnings
Retained Earnings	- 0.87	Property Plant And Equipment Net
Current Deferred Revenue	- 0.77	Net Debt
Cash	- 0.7	Net Debt
Cash And Short Term Investments	- 0.69	Net Debt
Net Tangible Assets	- 0.68	Common Stock Shares Outstanding